Cannabinoid Shows Positive Results in Treating Schizophrenia

Positive top-line results have been reported from an exploratory phase 2a placebo-controlled clinical trial of cannabidiol (CBD, GW Pharmaceuticals) in patients with schizophrenia who had failed to respond adequately to first-line antipsychotic medications.  DOES NOT CONTAIN THC.